Tristan Rousselle

Founder & CEO


Tristan ensures the development of global strategic partnerships and customer relationships to meet Aryballe’s long term vision for the potential of digital olfaction. Prior to founding Aryballe in 2014, Tristan was the founder and CEO of PX’Therapeutics which specialized in the development of therapeutic proteins. PX’Therapeutics was sold to Aguettan Biotech in 2012. Tristan holds a PhD in Cell Biology from Grenoble University (France).

Company Profile


Aryballe combines biochemistry, advanced optics and machine learning to mimic the human sense of smell. Odors captured by the silicon photonics-based core sensor in our NeOse Advance are analyzed by the cloud-based Aryballe Suite to provide objective, fast analysis. This enables customers to leverage odor data for improved decision making for R&D, quality control, and manufacturing.

All Agenda Items